Premium
Clinical evaluation of phendimetrazine bitartrate
Author(s) -
Ressler Charles,
Schneider Stanley H.
Publication year - 1961
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196126727
Subject(s) - placebo , medicine , urinalysis , blood pressure , incidence (geometry) , urine , physics , alternative medicine , pathology , optics
Clinical investigation of a phenmetrazine congener, phendimetrazine, was performed by using double blind controls. Of 50 obese patients who participated, 36 completed one adequate course of active drug or placebo and 20 completed both phases of the study. The average total weight lost and the average weight lost weekly by patients who received phendimetrazine were ahout 20 times as much as those of patients who received placebo. Comparison of the two groups showed no significant difference in undesirable effects. The over‐all incidence of subjective complaints or minor toxic reactions was negligible, and examination including pulse, blood pressure, blood count, and urinalysis showed no evidence of major change.